Bu çalışma kanserli hastaların, spiritüel iyilik hali ve psikolojik dayanıklılık düzeyi arasındaki ilişkinin incelenmesi amacı ile planlandı. Korelasyonel tanımlayıcı nitelikte olan bu çalışma, Eylül 2019-Aralık 2020 tarihleri arasında Haseki Eğitim Araştırma Hastanesi kemoterapi ünitesinde tedavi gören, 293 hasta yapılmıştır. Çalışmada; Anket formu, Spiritüel İyilik Ölçeği (FACIT SP12) Psikolo...

PURPOSE To compare the level of fatigue in survivors of Hodgkin's disease and their siblings, and to explore factors associated with increased fatigue. METHODS Survivors of Hodgkin's disease 5 years or more from diagnosis and their siblings completed a questionnaire study. Fatigue level was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) instrument, with ...

OBJECTIVES Fatigue is an important systemic symptom of rheumatoid arthritis (RA) but has rarely been evaluated consistently after initiation of treatment in RA patients. This study examined the effects of adalimumab (HUMIRA, Abbott Laboratories, Abbott Park, IL, USA), a fully human, anti-tumor necrosis factor (anti-TNF) monoclonal antibody, on reducing fatigue in patients with RA. METHODS A t...

Objective. Rheumatoid arthritis (RA) is associated with significant impairments in health-related quality of life (HRQOL). We evaluated patient-reported outcomes including HRQOL outcomes following adalimumab plus methotrexate (MTX) therapy in patients with early RA. Methods. PREMIER was a phase III, multicenter, randomized, double-blind, active-comparator clinical trial in early RA. Patients ag...

BACKGROUND Tunneled pleural catheters (TPC) are used in the management of malignant pleural effusions (MPE), but the impact of this palliative procedure on patient quality of life (QoL) has not been well described. OBJECTIVES To ascertain the impact of TPCs on symptoms and QoL of patients with recurrent MPE. METHODS Patients with recurrent MPE completed the EORTC QLQ-C30 and LC13 QoL questi...

OBJECTIVES To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227...

AIM Early morning symptoms (EMS) in people with COPD are associated with poor health, impaired activities and increased exacerbation risk. We describe the development and preliminary validation of the Manchester Early Morning Symptom Index (MEMSI) to quantify EMS in COPD. METHODS Focus groups and cognitive debriefing with patients with COPD were used to develop the potential item list, follow...

BACKGROUND To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, Eu...